EdiGene is a biotechnology company focused on translating cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer. The company leverages proprietary platforms to develop gene editing therapies for a range of diseases and conducts high throughput genome screening to dissect functional big data in biological contexts. EdiGene's proprietary High Throughput Genome Screening Platforms are built on advanced guide RNA design, extensive experience in cell library construction, cellular assays, and deep expertise in computational data analysis.

EdiGene operates in the biotechnology and pharmaceutical markets, primarily serving clients in the healthcare sector, including research institutions and pharmaceutical companies. The business model revolves around developing and licensing gene editing therapies and providing high throughput genome screening services. Revenue is generated through partnerships, licensing agreements, and service fees for genome screening.

Keywords: genome editing, gene therapy, biotechnology, cancer treatment, genetic diseases, drug discovery, high throughput screening, RNA design, cell library, computational analysis.